- Pfizer (NYSE:PFE) used IDWeek 2026 to present new Phase 3 results for its Lyme disease vaccine candidate.
- The company also reported Phase 3 data for its next generation pneumococcal vaccine program at the same conference.
- Pfizer shared real world effectiveness data on its RSV and other infectious disease vaccines in high risk groups.
- These IDWeek 2026 vaccine updates from Pfizer frame a broader story about its infectious disease pipeline that our research tracks. We have also flagged 4 warning signs for Pfizer.
This push into broader infectious disease vaccines is not unique to Pfizer. It can be useful to compare with peers exposed to similar themes through 34 healthcare AI stocks.
Pfizer is a US based pharmaceuticals group with a US$166.5 billion market value that develops and sells biopharmaceutical products globally. A broad infectious disease vaccine pipeline directly aligns with its core research and commercial footprint in vaccines and treatments.
2 things going right for Pfizer that this headline doesn't cover.
How Pfizer’s IDWeek 2026 vaccine data leans into the launched-growth story
Pfizer’s Narrative rests on launched and acquired products in areas like oncology, obesity and vaccines gradually replacing a shrinking COVID franchise, while tight cost control supports profitability. The IDWeek 2026 vaccine results plug into that bet by trying to show infectious disease products can do more of the heavy lifting.
"Expansion of launched and acquired products, which management now describes as running at around a US$13b annualized revenue rate and growing in the 20% range..."
See how the full story points towards a $28.88 fair value for Pfizer.
The IDWeek package gives concrete evidence on one of the Narrative’s key catalysts: the shift toward non COVID therapies through launched and late stage vaccines such as ABRYSVO, PREVNAR 20 and the Lyme candidate with Valneva. It also supports the idea that Pfizer’s infectious disease portfolio can keep contributing while management pushes obesity and oncology, rather than being a fading COVID add-on.
There is another side to this update that presses on risks already flagged by analysts, including high debt and a dividend that is not fully covered by earnings. A broader vaccine pipeline requires ongoing R&D and commercial spend, so the more Pfizer leans into infectious disease, the more important those planned US$9.7b of savings and pricing resilience become to keep the overall story intact.
For any investor, this vaccine news only really matters when set against the version of Pfizer’s long term story you choose to believe in and monitor over time.
The piece most Pfizer holders overlook sits in the cash flowing through the business
All the product stories sit on top of one quiet number: a view of what Pfizer could be worth if you only followed the cash moving through it and compared that with today’s share price. Find out exactly what Pfizer is worth today based on its cash flows.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com